SG10201804326SA - Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor - Google Patents

Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Info

Publication number
SG10201804326SA
SG10201804326SA SG10201804326SA SG10201804326SA SG10201804326SA SG 10201804326S A SG10201804326S A SG 10201804326SA SG 10201804326S A SG10201804326S A SG 10201804326SA SG 10201804326S A SG10201804326S A SG 10201804326SA SG 10201804326S A SG10201804326S A SG 10201804326SA
Authority
SG
Singapore
Prior art keywords
mediated rejection
methods
organ transplant
transplant patients
esterase inhibitor
Prior art date
Application number
SG10201804326SA
Other languages
English (en)
Inventor
Colin Broom
Marc Uknis
Original Assignee
Shire Viropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52016153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201804326S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma Inc filed Critical Shire Viropharma Inc
Publication of SG10201804326SA publication Critical patent/SG10201804326SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG10201804326SA 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor SG10201804326SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907550P 2013-11-22 2013-11-22
US201462029086P 2014-07-25 2014-07-25

Publications (1)

Publication Number Publication Date
SG10201804326SA true SG10201804326SA (en) 2018-06-28

Family

ID=52016153

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201804326SA SG10201804326SA (en) 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Country Status (23)

Country Link
US (3) US9895428B2 (hr)
EP (3) EP3494988B1 (hr)
JP (5) JP6431912B2 (hr)
KR (2) KR102384814B1 (hr)
CN (2) CN111388655A (hr)
AU (2) AU2014352846B2 (hr)
BR (1) BR112016011499A2 (hr)
CA (1) CA2930964A1 (hr)
CY (1) CY1121298T1 (hr)
DK (1) DK3071219T3 (hr)
ES (1) ES2708655T3 (hr)
HR (1) HRP20190184T1 (hr)
HU (1) HUE041809T2 (hr)
LT (1) LT3071219T (hr)
ME (1) ME03318B (hr)
MX (2) MX2016006656A (hr)
NZ (2) NZ719724A (hr)
PL (1) PL3071219T3 (hr)
PT (1) PT3071219T (hr)
RS (1) RS58343B1 (hr)
SG (1) SG10201804326SA (hr)
SI (1) SI3071219T1 (hr)
WO (1) WO2015077543A1 (hr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102384814B1 (ko) 2013-11-22 2022-04-08 다케다 야쿠힌 고교 가부시키가이샤 C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법
IL273185B1 (en) 2017-09-15 2024-06-01 Cedars Sinai Medical Center C1 esterase inhibitors for use in improving tissue function in uterine transplantation in patients
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
WO2021026507A1 (en) * 2019-08-08 2021-02-11 Cedars-Sinai Medical Center Methods of improving organ function
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
US20240000908A1 (en) 2020-11-20 2024-01-04 Csl Behring Gmbh Method for Treating Antibody-Mediated Rejection
CN113035369B (zh) * 2021-03-10 2021-12-03 浙江大学 一种肾移植抗感染药物剂量预测模型的构建方法
EP4366761A1 (en) 2021-07-09 2024-05-15 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU540709B2 (en) * 1982-04-12 1984-11-29 Mattel, Inc. Hair braiding
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
ES2516690T5 (es) 2005-06-07 2017-11-21 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad de serina proteasa y su uso en métodos y composiciones para el tratamiento de rechazo de injertos y promoción de supervivencia de injertos
WO2007103134A2 (en) * 2006-03-02 2007-09-13 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
CN104010656B (zh) * 2011-09-24 2016-02-24 德国杰特贝林生物制品有限公司 使用免疫球蛋白和c1-抑制剂的联合疗法
CN105188750A (zh) * 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
AU2014232912A1 (en) 2013-03-15 2015-09-03 Shire Viropharma Incorporated C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency
KR102384814B1 (ko) * 2013-11-22 2022-04-08 다케다 야쿠힌 고교 가부시키가이샤 C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법

Also Published As

Publication number Publication date
JP2019001831A (ja) 2019-01-10
NZ759187A (en) 2022-08-26
EP3494988A1 (en) 2019-06-12
PL3071219T3 (pl) 2019-04-30
HRP20190184T1 (hr) 2019-03-22
JP2016537380A (ja) 2016-12-01
RS58343B1 (sr) 2019-03-29
EP3071219B1 (en) 2018-11-14
ES2708655T3 (es) 2019-04-10
KR102312817B1 (ko) 2021-10-13
ME03318B (me) 2019-10-20
AU2014352846A1 (en) 2016-06-02
CN111388655A (zh) 2020-07-10
KR102384814B1 (ko) 2022-04-08
EP3071219A1 (en) 2016-09-28
AU2020200015B2 (en) 2022-03-10
PT3071219T (pt) 2019-02-06
AU2020200015A1 (en) 2020-01-30
KR20160079821A (ko) 2016-07-06
MX2021000332A (es) 2021-04-13
JP2022179637A (ja) 2022-12-02
JP6620206B2 (ja) 2019-12-11
SI3071219T1 (sl) 2019-03-29
MX2016006656A (es) 2016-09-06
US20150147319A1 (en) 2015-05-28
LT3071219T (lt) 2019-01-10
JP2019023233A (ja) 2019-02-14
CN105744949A (zh) 2016-07-06
CA2930964A1 (en) 2015-05-28
JP6431912B2 (ja) 2018-11-28
EP4162947A1 (en) 2023-04-12
US9895428B2 (en) 2018-02-20
HUE041809T2 (hu) 2019-05-28
EP3494988B1 (en) 2022-08-03
US20180104319A1 (en) 2018-04-19
US20200360495A1 (en) 2020-11-19
CY1121298T1 (el) 2020-05-29
AU2014352846B2 (en) 2019-10-03
BR112016011499A2 (pt) 2020-10-27
NZ719724A (en) 2022-08-26
WO2015077543A1 (en) 2015-05-28
JP2021063141A (ja) 2021-04-22
DK3071219T3 (en) 2019-02-25
KR20210125118A (ko) 2021-10-15

Similar Documents

Publication Publication Date Title
SG10201804326SA (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
WO2017096309A8 (en) Methods of treatment of malignancies
NZ709635A (en) Bcl-2bcl-xl inhibitors and therapeutic methods using the same
DK2970867T3 (da) Plantevækstfremmende bakterier og anvendelsesfremgangsmåder
CL2014001162A1 (es) Inoculantes microbianos que comprenden lactobacillus; composicion fertilizante que comprenden los mismos; metodo para aumentar crecimiento y/o la productividad de plantas.
CL2007003622A1 (es) Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
PH12015500694A1 (en) Compositions and methods for enhancing plant growth
GB2538178A (en) Viscosifier polymer for treatment of a subterranean formation
MX2015013622A (es) Composiciones y metodos para potenciar el crecimiento de las plantas.
MX2016009428A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
EP3681525A4 (en) COMPOSITION AND METHOD OF PROCESSING AUTISM
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
MX2016002276A (es) Transformación de la lenteja de agua y sus usos.
MX2015012681A (es) Composiciones y metodos para tratar patogenos fungicos y bacterianos.
IN2015DN03329A (hr)
MX2017007297A (es) Composiciones y metodos para la introduccion de micronutrientes.
TW201611841A (en) Method for treatment of prostatic hyperplasia and/or ameliorating urinary disturbance with banana flower extract
IL273185A (en) C1 esterase inhibitors for use in improving tissue function in uterine transplantation in patients
MX369097B (es) Metodo para expandir las celulas madre adultas de sangre entera.
MX2018000571A (es) Procedimiento para el aclareo de frutas.
DE10772664T8 (de) Verfahren zur behandlung von blasenhyperaktivität und vorrichtung zur lagerung und verabreichung topischer oxybutynin-zusammensetzungen
SG11202001273RA (en) Method for controlling serine content of solanaceous plant, solanaceous plant, and method for identifying solanaceous plant cultivation method
MY197963A (en) Algae treatment method
JOP20170174A1 (ar) محطة لمعالجة المياه المهدورة وطريقة للمعالجة